These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28835084)

  • 1. [A multicenter clinical study for the comparison of S-1 versus capecitabine in the treatment of advanced breast cancer].
    Li Y; Jiang D; Wu YY; Li LL; Cui YZ; Dong Q
    Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):607-612. PubMed ID: 28835084
    [No Abstract]   [Full Text] [Related]  

  • 2. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial.
    Hamaguchi T; Shimada Y; Mizusawa J; Kinugasa Y; Kanemitsu Y; Ohue M; Fujii S; Takiguchi N; Yatsuoka T; Takii Y; Ojima H; Masuko H; Kubo Y; Mishima H; Yamaguchi T; Bando H; Sato T; Kato T; Nakamura K; Fukuda H; Moriya Y
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):47-56. PubMed ID: 29079411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis.
    He AB; Peng XL; Song J; Zhang JX; Dong WG; Luo RF; Tang Y
    World J Gastroenterol; 2015 Apr; 21(14):4358-64. PubMed ID: 25892887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis.
    Chen J; Wang J; Xu T
    Medicine (Baltimore); 2019 Jul; 98(30):e16667. PubMed ID: 31348323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.
    Li J; You J; Si W; Zhu Y; Chen Y; Yang B; Han C; Linghu R; Zhang X; Jiao S; Yang J
    Medicine (Baltimore); 2015 Oct; 94(41):e1340. PubMed ID: 26469889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of S-1 monotherapy in the treatment of advanced breast cancer in elderly patients.
    Cui S; Zhao Q; Ye M; You D; Sun Y
    Pak J Pharm Sci; 2018 Sep; 31(5(Special)):2299-2302. PubMed ID: 30463829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
    Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
    Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of capecitabine-based versus S-1-based chemotherapy for metastatic or recurrent gastric cancer: a systematic review and meta-analysis of clinical randomized trials.
    Feng Z; Yan P; Hou X; Feng J; He X; Yang K
    Ann Palliat Med; 2020 May; 9(3):883-894. PubMed ID: 32389017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].
    Huang HY; Jiang ZF; Wang T; Zhang SH; Bian L; Cao Y; Wu SK; Song ST
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):850-3. PubMed ID: 22335952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
    Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
    Wu Q; Fu Y; Wen W; Xi T; Zhao G
    J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
    Taguchi T; Morimoto K; Horikoshi N; Takashima S; Toge T; Kimura M; Sano M; Aoyama H; Ota J; Noguchi S
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1035-43. PubMed ID: 9644319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
    Saeki T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Taguchi T
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):539-47. PubMed ID: 15114697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
    Zhang X; Cao C; Zhang Q; Chen Y; Gu D; Shen Y; Gong Y; Chen J; Tang C
    PLoS One; 2014; 9(1):e84230. PubMed ID: 24392116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
    Yamamoto D; Iwase S; Tsubota Y; Ariyoshi K; Kawaguchi T; Miyaji T; Sueoka N; Yamamoto C; Teramoto S; Odagiri H; Kitamura K; Nagumo Y; Yamaguchi T
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1183-9. PubMed ID: 25862350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials.
    Yin W; Pei G; Liu G; Huang L; Gao S; Feng X
    Oncotarget; 2015 Nov; 6(36):39365-72. PubMed ID: 26420815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO)].
    Yokoyama T; Tokuhara H; Egawa T; Hashimoto O; Seki H; Koyanagi K; Bessho T
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1667-70. PubMed ID: 19838025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
    Masuda N; Lee SJ; Ohtani S; Im YH; Lee ES; Yokota I; Kuroi K; Im SA; Park BW; Kim SB; Yanagita Y; Ohno S; Takao S; Aogi K; Iwata H; Jeong J; Kim A; Park KH; Sasano H; Ohashi Y; Toi M
    N Engl J Med; 2017 Jun; 376(22):2147-2159. PubMed ID: 28564564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of S-1 in Advanced Non-small Cell Lung Cancer Patients Treated 
with More Than Two Lines of Chemotherapy].
    Yin Y; Wu B; Huang Z; Zhuang W; Xu Z; Huang C; Huang Y; Zhang J
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):437-444. PubMed ID: 29945701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.